Exact Mass: 279.0654
Exact Mass Matches: 279.0654
Found 68 metabolites which its exact mass value is equals to given mass value 279.0654,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Cidofovir
Cidofovir is only found in individuals that have used or taken this drug. It is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. [Wikipedia]Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent D004791 - Enzyme Inhibitors
N-[4'-hydroxy-(E)-cinnamoyl]-L-aspartic acid
N-[4-hydroxy-(E)-cinnamoyl]-L-aspartic acid is a cocoa metabolite from gut microflora. It is found n urine. Constituent of Arabidopsis thalianaand is also found in roasted cocoa beans and coffee powder [CCD].
(2R,4S)-2-Aminoformyl-6-fluoro-spiro[chroman-4,4'-imidazolidine]-2',5'-dione
Fexinidazole
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01C - Agents against leishmaniasis and trypanosomiasis > P01CA - Nitroimidazole derivatives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
3-(2-amino-4,6-dioxo-3,4,5,6-tetrahydro-pteridin-7-yl)-2-oxo-propionic acid methyl ester|Erythropterin-methylester
ZLJ-6
N-[4-hydroxy-(E)-cinnamoyl]-L-aspartic acid
1-CYCLOPROPYL-6,7-DIFLUORO-5-METHYL-4-OXO-3-QUINOLINE CARBOXYLIC ACID
1-[3-chloro-5-(trifluoromethyl)-2-pyridyl]-1,4-diazepane
4-[2-(chloromethyl)-4-(trifluoromethyl)phenyl]morpholine
(s)-(+)-3-(benzyloxycarbonyl)-5-oxo-4-oxazolidineacetic acid
4-[4-Chloro-3-(trifluoromethyl)phenyl]-4-piperidinol
(2-(BUTYLTHIO)-5-(TRIFLUOROMETHYL)PYRIDIN-3-YL)BORONIC ACID
3-benzylhydroxy-6-hydroxymethylpyridine-2-carboxaldehyde hydrochloride
(2-(ISOBUTYLTHIO)-5-(TRIFLUOROMETHYL)PYRIDIN-3-YL)BORONIC ACID
4-Chloro-6-ethoxyquinoline-3-carboxylic acid ethyl ester
Letosteine
R - Respiratory system > R05 - Cough and cold preparations > R05C - Expectorants, excl. combinations with cough suppressants > R05CB - Mucolytics C78273 - Agent Affecting Respiratory System > C74536 - Mucolytic Agent D019141 - Respiratory System Agents > D005100 - Expectorants
2-[1-(4-methylphenyl)sulfonylpyrrol-3-yl]acetic acid
[5-furan-2-yl-4-(2-methyl-allyl)-4 h-[1,2,4]triazol-3-ylsulfanyl]-acetic acid
7-PHENYL-1-(PROP-2-YNYL)-1H-PYRIMIDO[4,5-D][1,3]OXAZINE-2,4-DIONE
Cytarabine hydrochloride
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.
(+/-)-8,9-Difluoro-5-methyl-6,7-dihydro-1-oxo-1H,5H-bnezo[i,j]quinolizine-2-carboxylic acid
ETHYL 8-CHLORO-1-ETHYL-4-OXO-4H-QUINOLIZINE-3-CARBOXYLATE
methyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
2-Amino-5-beta-D-ribofuranosyl-4(1H)-pyrimidinone hydrochloride
Ethyl 2-amino-4-(4-fluorophenyl)-5-methyl-thiophene-3-carboxylate
3-Quinolinecarbonitrile,2-amino-6-chloro-4-phenyl-
3-(3-Fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile
3-chloro-2,2-dimethyl-N-[4-(trifluoromethyl)phenyl]propanamide
Taribavirin hydrochloride
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent
6-Fluoro-2,5-dioxo-2,3-dihydrospiro[chromene-4,4-imidazolidine]-2-carboxamide
[2-(2,3-Dimethoxyphenyl)-1,3-thiazol-4-yl]acetic acid
Dimethyl 2-[[bis(methylsulfanyl)methylideneamino]methyl]butanedioate
(2S,4R)-2-Aminoformyl-6-fluoro-spiro[chroman-4,4-imidazolidine]-2,5-dione
But-3-enyl-[5-(4-chloro-phenyl)-3,6-dihydro-[1,3,4]thiadiazin-2-ylidene]-amine
Fexinidazole
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01C - Agents against leishmaniasis and trypanosomiasis > P01CA - Nitroimidazole derivatives C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
2-[4-(Trifluoromethoxy)phenyl]imidazo[1,2-a]pyrimidine
2-[2-(Butan-2-ylidene)hydrazino]-4-(4-chlorophenyl)-1,3-thiazole
2-Hydroxy-4-methoxybenzoic acid (2-methyl-4-thiazolyl)methyl ester
2-Chloro-3-(3-methoxypropylimino)naphthalene-1,4-dione
6-Chloro-3-(3,3-dimethyl-2-oxobutyl)-1,4-benzoxazin-2-one
6-Chloro-3-(4-methyl-2-oxopentyl)-1,4-benzoxazin-2-one
Cidofovir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AB - Nucleosides and nucleotides excl. reverse transcriptase inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent D004791 - Enzyme Inhibitors
UCM-1306
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD)[1].
